Inovio Pharmaceuticals
124 hedge funds and large institutions have $21.6M invested in Inovio Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 23 increasing their positions, 44 reducing their positions, and 24 closing their positions.
1,247% more call options, than puts
Call options by funds: $229K | Put options by funds: $17K
0.55% less ownership
Funds ownership: 2.27% → 1.73% (-0.55%)
7% less funds holding
Funds holding: 133 → 124 (-9)
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
33% less capital invested
Capital invested by funds: $32.1M → $21.6M (-$10.4M)
48% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$212K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$207K |
| 3 |
GAA
Green Alpha Advisors
Niwot,
Colorado
|
+$178K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$137K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$73.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.36M |
| 2 |
Jane Street
New York
|
-$1.35M |
| 3 |
D.E. Shaw & Co
New York
|
-$959K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$519K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$459K |
INO Hedge Fund Activity: Q3 2023 in Review
124 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2023, worth a combined $21.6M — down 33% from $32.1M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of INO and 17 opened new positions — a net loss of 7 holders — while 44 trimmed existing stakes and 23 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $212K. The largest seller was JP Morgan Chase, cutting an estimated $1.36M.
- 124 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2023, down from 133 in Q2 2023.
- Funds reported $21.6M of Inovio Pharmaceuticals stock for Q3 2023, down 33% quarter-over-quarter.
- 17 funds opened new Inovio Pharmaceuticals positions in Q3 2023 and 24 closed out, a net change of -7 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2023 was Acadian Asset Management, an estimated $212K added.
- The largest Inovio Pharmaceuticals seller in Q3 2023 was JP Morgan Chase, an estimated $1.36M sold.
Based on aggregated 13F filings for Q3 2023.